HBV Treatment: These studies examine the effectiveness of various antiviral and pegylated interferon drugs used either individually or in combination. These studies also examine the role of genotype, viral load, HBeAg status, and liver health in each treatmentís success or failure.



        890. Durability of Adefovir Dipivoxil-Induced HBeAg Loss Following Long-term Additional Therapy in Patients with YMDD Mutants of Hepatitis B Virus



        911. Clevudine Was Superior to Lamivudine in the Patients with HBeAg(+) Chronic Hepatitis B



        969. Entecavir Induced HBV DNA Suppression at 12 Weeks in Treatment-Navie Patients with Chronic Hepatitis B is a Good Predictive Factor for Virological Response at 48 Weeks


Adefovir and Lamivudine Resistance

        513. Addition of Adefovir Dipivoxil to Lamivudine in Chronic Hepatitis B Patients with YMDD Mutation: The long-term follow-up results

        514. Demonstration of YMDD Mutation in Liver Tissues of 14 Chronic Hepatitis B Patients under Lamivudine Therapy

        518. Hepatitis B Genotype Distribution and High Frequency of Lamivudine Resistance Mutations in Brazilian HIV/Hepatitis B Virus Co-infected Patients

        888. Lamivudine-resistant Mutation Among Treatment-naive Hepatitis B Patients Is Common and May Be Associated with Treatment Failure

        897. High Risk of Renal Impairment and Arterial Hypertension During Long-term Adefovir and Lamivudine Combination Therapy in Patients with Lamivudine-resistant Chronic Hepatitis B


Antiviral Resistance Ė General

        884. Primary Resistance Mutations Against Nucleos(t)ide Analogues in Treatment-naÔve Patients with HBV-infection



        1622. The Control of HBV Replication That Leads to HBeAg/anti-HBe Seroconversion Does Not Prevent the Emergence of Pre-Core Defective Variants in Genotype D-Infected Children



        870. Higher Levels of HBV-DNA in Genotypes B and C Compared to Genotypes A and D

        952. HBeAg Seroconversion Induced by Nucleos(t)ide Analogues in Chronic Hepatitis B Is Not Durable in a Majority of Cases

        976. Cost-effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg-negative (-) Patients with Chronic Hepatitis B (CHB) in the USA



        842. Precore and Basal Core Promoter Mutations Restore the Reduced Replication Efficacy of Tenofovir-resistance Associated rtA194T Polymerase Mutations of the Hepatitis B Virus

        866. Immunological Profile of Peripheral Blood Mononuclear Cells, NK T Cells and Dendritic Cells in Chronic HBV-infected Patients Treated with Tenofovir Disoproxil Fumarate

        880. Presence of rtA194T at Baseline Does Not Reduce Efficacy to Tenofovir(TDF) in Patients with Lamivudine(LAM)-resistant Chronic Hepatitis B

        907. Tenofovir-based Highly Active Antiretroviral Therapy (HAART) Is Associated with High Rates of HBV DNA Suppression and HBeAg Seroconversion in Thai HIV-HBV Coinfected Patients

        913. Detection of Mutations Associated with Resistance to Nucleos(t)ide Analogs in Patients with HBV Infection During Treatment with Tenofovir

        920. Higher Frequency of Selection of Tenofovir-resistant Mutations in Lamivudine Exposed Compared to NaÔve CHBV Patients During Tenofovir Antiviral Therapy

        932. Excellent Treatment Response to Tenofovir (TDF)Monotherapy in Chronic Hepatitis B (CHB) Patients with Prior Suboptimal Response to Entecavir (ETV) Monotherapy

        955. Tenofovir is Equally Active In Vitro Against Wild-type HBV Clinical Isolates of Genotypes A−H

        977. Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 MG QD

        980. Tenofovir Disoproxil Fumarate (TDF) Versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B Participating in Studies 102 and 103

        983. A Prospective Study of Tenofovir Disoproxil Fumarate for Patients with Chronic Hepatitis B Who Have Previously Failed Lamivudine and Have Significant Viral Replication Despite at Least 24 Weeks of Adefovir Dipivoxil Therapy

        985. Combination of Entecavir and Tenofovir as a Rescue Therapy Is Safe and Highly Efficient in Cirrhotic HBV Mono-infected Patients with the History of Multiple Previous Treatment Failures